Robust Findings for HER2 TKI in NSCLC

Among 74 patients newly diagnosed with HER2-mutant NSCLC who received a daily dose of zongertinib, the objective response rate was 76% and the median progression-free survival was 14.4 months. That bests chemotherapy, to which about 30% of patients typically respond for less than 7 months.

Publication Details

Journal
Cancer Discovery
Published
2026-05-02
DOI
https://doi.org/10.1158/2159-8290.cd-nw2026-0051
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Robust Findings for HER2 TKI in NSCLC

Cancer Discovery
Lung Cancer Treatments and Mutations
article

Robust Findings for HER2 TKI in NSCLC

article en

Abstract

Among 74 patients newly diagnosed with HER2-mutant NSCLC who received a daily dose of zongertinib, the objective response rate was 76% and the median progression-free survival was 14.4 months. That bests chemotherapy, to which about 30% of patients typically respond for less than 7 months.

Cancer Discovery
Good health and well-being
Openalex Percentile: Top 11%
Lung Cancer Treatments and Mutations
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Robust Findings for HER2 TKI in NSCLC · Cancer Discovery (2026) | TGRS Research Map | TGRS